Clinical Trial: A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07915856) titled 'A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors' on Oct. 30.

Brief Summary: This Phase 1, first-in-human, open-label, multicenter study evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QLS5314 monotherapy in adults with advanced solid tumors. The study includes Phase 1a dose escalation, Phase 1a dose expansion, and Phase 1b efficacy expansion. It also aims to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose (RP2D).

Study Start Date: Jan. 26, 2027

Study Type: INTERVENTIONAL

Condition: Advanced So...